Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice

International Journal of Molecular Medicine

Volumn 17, Issue 6, 2006, Pages 997-1004

  Naito, Yuji ^a   Katada, Kazuhiro ^a   Takagi, Tomohisa ^a   Tsuboi, Hisato ^a   Isozaki, Yutaka ^a   Handa, Osamu ^a   Kokura, Satoshi ^a   Yoshida, Norimasa ^a   Ichikawa, Hiroshi ^b   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY   (Japan)

Author keywords

Dextran sulfate sodium; eNOS; Inflammation; Neutrophil activation; Rosuvastatin; Tumor necrosis factor

Indexed keywords

2,2 DIMETHYL 5 HYDROXY 1 PYRROLIDINYLOXY; 2,2-DIMETHYL-5-HYDROXY-1-PYRROLIDINYLOXY; 5,5 DIMETHYL 5 HYDROPEROXY 1 PYRROLIDINYLOXY; 5,5-DIMETHYL-5-HYDROPEROXY-1-PYRROLIDINYLOXY; AMINE OXIDE; DEXTRAN SULFATE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; PEROXIDASE; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; SULFONAMIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COLITIS; COLON; DRUG EFFECT; ENTERITIS; FEMALE; GENETICS; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; COLITIS; COLON; CYCLIC N-OXIDES; DEXTRAN SULFATE; FEMALE; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATORY BOWEL DISEASES; MICE; MICE, INBRED BALB C; NITRIC OXIDE SYNTHASE TYPE III; PEROXIDASE; PYRIMIDINES; RNA, MESSENGER; SULFONAMIDES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745727522     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.17.6.997     Document Type: Article

References (43)

1. Vainer B: Intercellular adhesion molecule-1 (ICAM-1) in ulcerative colitis: presence, visualization, and significance. Inflamm Res 54: 313-327, 2005.
2. Harlan JM and Winn RK: Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit Care Med 30: S214-S219, 2002.
3. Maron DJ, Fazio S and Linton MF: Current perspectives on statins. Circulation 101: 207-213, 2000.
4. Oda H and Keane WF: Recent advances in statins and the kidney. Kidney Int Suppl 71: S2-S5, 1999.
5. Endres M and Laufs U: Effects of statins on endothelium and signaling mechanisms. Stroke 35: 2708-2711, 2004.
6. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7: 687-692, 2001. (Pubitemid 32588024)
7. Ikeda Y, Young LH and Lefer AM: Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. J Cardiovasc Pharmacol 41: 649-656, 2003.
8. Bulhak A, Sjoquist PO and Pernow J: Rosuvastatin protects the myocardium against ischaemia-reperfusion injury via inhibition of GGPP synthesis. Cardiovasc J S Afr 15: S11, 2004.
9. Bulhak AA, Gourine AV, Gonon AT, Sjoquist PO, Valen G and Pernow J: Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level. Acta Physiol Scand 183: 151-159, 2005.
10. Weinberg EO, Scherrer-Crosbie M, Picard MH, et al: Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion. Am J Physiol Heart Circ Physiol 288: H1802-H1809, 2005.
11. Di Napoli P, Taccardi AA, Grilli A, et al: Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 66: 462-471, 2005. (Pubitemid 40725758)
12. Sironi L, Gianazza E, Gelosa P, et al: Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arterioscler Thromb Vasc Biol 25: 598-603, 2005.
13. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y and Nakaya R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702, 1990.
14. Naito Y, Takagi T, Ishikawa T, et al: The inducible nitric oxide synthase inhibitor ONO-1714 blunts dextran sulfate sodium colitis in mice. Eur J Pharmacol 412: 91-99, 2001. (Pubitemid 32149773)
15. Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE and Buchler MW: Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion 62: 240-248, 2000.
16. Naito Y, Takagi T, Ishikawa T, et al: alpha-Phenyl-N-tert-butylnitrone provides protection from dextran sulfate sodium-induced colitis in mice. Antioxid Redox Signal 4: 195-206, 2002.
17. Cooper HS, Murthy SN, Shah RS and Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249, 1993.
18. Naito Y, Takagi T, Kuroda M, et al: An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice. Inflamm Res 53: 462-468, 2004.
19. Naito Y, Takagi T, Katada K, et al: Partially hydrolyzed guar gum down-regulates colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. J Nutr Biochem (In press).
20. Grisham MB, Hernandez LA and Granger DN: Xanthine oxidase and neutrophil infiltration in intestinal ischemia. Am J Physiol 252: G567-G574, 1986.
21. Ohkawa H, Ohnishi N and Yagi K: Assay for lipid peroxides for animal tissues by thiobarbituric acid reaction. Anal Biochem 95: 351-358, 1986.
22. Lowry OH, Rosenbrough NJ, Farr AL and Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275, 1951.
23. Miyagawa H, Yoshikawa T, Tanigawa T, Yoshida N, Sugino S and Kondo M: Measurement of serum superoxide dismutase activity by electron spin resonance. J Clin Biochem Nutr 5: 1-7, 1988.
24. Tanigawa T: Determination of hydroxyl radical scavenging activity by electron spin resonance. J Kyoto Pref Univ Med 99: 133-143, 1990.
25. Niki E and Komuro E: Inhibition of peroxidation of membranes. Basic Life Sci 49: 561-566, 1988.
26. Niki E, Noguchi N and Gotoh N: Dynamics of lipid peroxidation and its inhibition by antioxidants. Biochem Soc Trans 21: 313-317, 1993.
27. Naito Y, Takagi T, Handa O, et al: Role of superoxide and lipid peroxidation in the pathogenesis of dextran sulfate sodiumcolitis in mice. ITE Lett 2: 663-667, 2001.
28. Naito Y, Takagi T, Matsuyama K, et al: Effect of a novel water-soluble vitamin E derivative, 2-(a-D-glucopyranoyl)methyl-2,5,7,8-tetramethylchroman-6- ol, on dextran sulfate sodium-induced colitis in mice. J Clin Biochem Nutr 31: 59-67, 2002.
29. Breider MA, Eppinger M and Gough A: Intercellular adhesion molecule-1 expression in dextran sodium sulfate-induced colitis in rats. Vet Pathol 34: 598-604, 1997.
30. Natsui M, Kawasaki K, Takizawa H, et al: Selective depletion of neutrophils by a monoclonal antibody, RP-3, suppresses dextran sulphate sodium-induced colitis in rats. J Gastroenterol Hepatol 12: 801-808, 1997.
31. Taniguchi T, Tsukada H, Nakamura H, et al: Effects of the anti-ICAM-1 monoclonal antibody on dextran sodium sulphate-induced colitis in rats. J Gastroenterol Hepatol 13: 945-949, 1998. (Pubitemid 28448968)
32. Honjo M, Tanihara H, Nishijima K, et al: Statin inhibits leukocyte-endothelial interaction and prevents neuronal death induced by ischemia-reperfusion injury in the rat retina. Arch Ophthalmol 120: 1707-1713, 2002. (Pubitemid 36401807)
33. Naidu BV, Woolley SM, Farivar AS, Thomas R, Fraga C and Mulligan MS: Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion. J Thorac Cardiovasc Surg 126: 482-489, 2003.
34. Rutgeerts PJ: Review article: efficacy of infliximab in Crohn's disease - induction and maintenance of remission. Aliment Pharmacol Ther 13: 9-15; discussion 38, 1999.
35. Kojouharoff G, Hans W, Obermeier F, et al: Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 107: 353-358, 1997.
36. Takagi T, Naito Y, Tomatsuri N, et al: Pioglitazone, a PPAR-gamma ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-kappaB-cytokine cascade. Redox Rep 7: 283-289, 2002. (Pubitemid 36032915)
37. Kleemann R, Princen HM, Emeis JJ, et al: Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 108: 1368-1374, 2003.
38. Wolfrum S, Dendorfer A, Schutt M, et al: Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 44: 348-355, 2004.
39. Endres M, Laufs U, Huang Z, et al: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95: 8880-8885, 1998.
40. Sasaki M, Bharwani S, Jordan P, et al: The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J Pharmacol Exp Ther 305: 78-85, 2003.
41. Laufs U, La Fata V, Plutzky J and Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135, 1998. (Pubitemid 28152885)
42. Kubes P, Suzuki M and Granger DN: Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88: 4651-4655, 1991. (Pubitemid 21914599)
43. Lefer AM: Nitric oxide: nature's naturally occurring leukocyte inhibitor. Circulation 95: 553-554, 1997.